Ping An Biomedical Co., Ltd. has entered into a letter of intent with Future Biotechnology Group Co., Limited for the planned acquisition of three tumor cell-related medical technology patents. This acquisition is significant as it aims to enhance Ping An's intellectual property portfolio in the oncology sector.
The planned acquisition, which is valued between $2 million and $2.5 million, covers patents related to oncology diagnosis and treatment, cell detection and bioengineering, as well as biomarker and DNA probe technologies. The move underscores the company's strategy to establish a strong foothold in healthcare and biomedical research and development.
Ping An Biomedical, listed on Nasdaq under the ticker PASW, is recognized for its innovative solutions in healthcare and biomedical technology. The company operates within the apparel and other finished products of fabrics and similar materials sector, as denoted by its SIC code 2300.
According to the filing dated October 26, 2026, the acquisition is subject to a final agreement that will be prepared and executed by both parties. The company issued a press release on October 22, 2026, detailing the planned acquisition and its strategic importance.
Management believes that this acquisition aligns with long-term trends in the healthcare market, particularly the increasing importance of oncology-related diagnostics and biotechnologies. The company intends to gradually build a healthcare technology asset reserve that supports ownership of core intellectual properties and potential pathways for development, collaboration, and licensing.
Upon completion of the acquisition, Ping An plans to incorporate the patents into its healthcare technology intellectual property reserve. Management will evaluate further development pathways, which may include internal research and development, collaboration with partners, or licensing.
Mr. Pijun Liu, Chief Executive Officer and Chairman of the Board, stated, “Building a focused healthcare technology IP reserve is a measured step aligned with our long-term view of the medical market. This planned acquisition is a concrete step in our healthcare and biomedical strategy.”
While the acquisition is not expected to generate immediate revenue, it is seen as a foundational step for future healthcare initiatives. The company will keep stakeholders informed as it progresses through the necessary due diligence and agreement stages.
As the healthcare landscape continues to evolve, Ping An Biomedical's strategic acquisition reflects its commitment to innovation and growth in the oncology and biotechnology fields.